Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis

BackgroundTriple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer and the major phenotype of BRCA related hereditary breast cancer. Platinum is a promising chemotherapeutic agent for TNBC. However, its efficacy for breast cancer with BRCA germline mutation remain...

Full description

Bibliographic Details
Main Authors: Chang-Jun Wang, Ying Xu, Yan Lin, Han-Jiang Zhu, Yi-Dong Zhou, Feng Mao, Xiao-Hui Zhang, Xin Huang, Ying Zhong, Qiang Sun, Cheng-Gang Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Oncology
Subjects:
breast cancer
platinum
BRCA gene
neoadjuvant chemotherapy
pathological complete response
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.592998/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.592998/full

Similar Items